Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | GLS | O94925 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464008 | 0.85 | PKM (0.66) | NAMPTMEN1KMT2APKMNPC1 | |
| SCHEMBL5472671 | 0.82 | NPC1 (0.67) | MEN1KMT2APKMNPC1 | |
| SCHEMBL5464429 | 0.80 | MEN1 (0.60) | NAMPTMEN1KMT2APKMCHRM4 | |
| SCHEMBL4982704 | 0.80 | CARM1 (0.55) | NAMPTMAPK14ROCK2CARM1PRMT6 | |
| SCHEMBL13873824 | 0.79 | EPHX2 (0.59) | NAMPTKITMEN1KMT2AMAPK14 | |
| SCHEMBL5724446 | 0.79 | MAPK14 (0.63) | NAMPTMAPK14ROCK2GLSROCK1 | |
| SCHEMBL13873761 | 0.78 | EPHX2 (0.67) | NAMPTKITMEN1KMT2AMAPK14 | |
| SCHEMBL13873701 | 0.78 | CHRM4 (0.50) | NAMPTKITMEN1KMT2AMAPK14 | |
| SCHEMBL13873786 | 0.78 | EPHX2 (0.69) | NAMPTKITMAPK14ROCK2CHRM4 | |
| SCHEMBL5472340 | 0.78 | KMT2A (0.60) | MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | NAMPT 3859/4885KIT 134/4885MEN1 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.